NCT07260201Completed
Triglyceride-Glucose and TGI-BMI Indices Compared With HOMA-IR
Evaluating the Triglyceride-Glucose Index and TGI-BMI for Insulin Resistance Assessment: A Comparative Study With HOMA-IR
Source: ClinicalTrials.gov · Last updated 3 Dec 2025
Brief summary (registry, in English)
Insulin resistance plays a key role in the development of type 2 diabetes, metabolic syndrome, and heart disease. The most common way to measure insulin resistance is the HOMA-IR index, but it requires fasting insulin tests, which are not always available in clinical practice. This study aims to assess two simpler and more accessible alternatives: the triglyceride-glucose index (TGI) and its body mass index-adjusted version (TGI-BMI). Data from 150 adult patients were analyzed retrospectively and divided into groups according to their insulin resistance status. Standard laboratory and body measurements were compared between groups, and statistical analyses were used to determine how well TGI and TGI-BMI identify insulin resistance. The results showed that both TGI and TGI-BMI were closely related to insulin resistance and demonstrated high diagnostic accuracy, similar to HOMA-IR. The TGI-BMI index was particularly effective in individuals with obesity. These findings suggest that TGI and TGI-BMI could serve as practical, low-cost alternatives to HOMA-IR for evaluating insulin resistance in clinical and population settings where insulin testing is not routinely available.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 150 (actual)
- First submitted
- 18 Nov 2025
- Start date
- 1 Dec 2024
- Primary completion date
- 20 Oct 2025
- Lead sponsor
- Hisar Intercontinental Hospital
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07260201
What you commit to
- Study type: Observational
- Participants enrolled: 150
- From 1 Dec 2024 to the primary completion date, 20 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Patients were excluded if they had any of the following:
- Known endocrine disorders (e.g., thyroid dysfunction, Cushing's syndrome)
- Chronic kidney or liver disease
- Active infection or systemic inflammatory disease
- Ongoing use of medications known to affect glucose or lipid metabolism (e.g., corticosteroids, statins, metformin, or insulin)
- Incomplete or missing laboratory data
Who the study is looking for
- Eligible participants were adults aged 18-65 years with complete fasting biochemical and anthropometric data. Only patients who were not receiving antidiabetic medications at the time of evaluation were included.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hisar Intercontinental Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.